Literature DB >> 762209

Determination of quinidine and its major metabolites by high-performance liquid chromatography.

T W Guentert, P E Coates, R A Upton, D L Combs, S Riegelman.   

Abstract

A specific and precise assay, capable of quantitating in human plasma simultaneously but separately quinidine, dihydroquinidine and the quinidine metabolites 2'-quinidinone, 3-OH-quinidine and a third metabolite found--tentatively identified as the product formed by rearrangement of quinidine-N-oxide-is reported. The assay uses a normal phase high-performance liquid chromatographic (HPLC) system with a variable-wavelength UV detector at 235 nm and has a limit of sensitivity at approximately 20 ng/ml. The mobile phase consists of hexanes-ethanol-ethanolamine (91.5:8.47:0.03). A 2-ml plasma sample is worked up by adding primaquine base as an internal standard and extracting with ether-dichlormethane-isopropanol (6:4:1). The organic extract is evaporated and the residue reconstituted in 100-600 micron1 of mobile phase and an aliquot injected onto the column. Comparison of this procedure with the Edgar and Sokolow (dichloroethane) extraction--fluorescence procedure and with the Cramer and Isaksson (benzene) double extraction--fluorescence assay indicates that both fluorescence procedures give quinidine concentrations up to 2.3 times those determined by HPLC. These discrepancies were shown to be due to carry-over of metabolites and some extraneous background fluorescence.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 762209     DOI: 10.1016/s0378-4347(00)82063-0

Source DB:  PubMed          Journal:  J Chromatogr


  12 in total

1.  Comparison of two long-acting forms of quinidine.

Authors:  A Leizorovicz; C Piolat; J P Boissel; B Sanchini; S Ferry
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

2.  Quinidine determination in serum: enzyme immunoassay (EIA) V HPLC.

Authors:  H R Ha; G Kewitz; M Wenk; F Follath
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

3.  The effect of quinidine and its metabolites on the electrocardiogram and systolic time intervals: concentration--effect relationships.

Authors:  N H Holford; P E Coates; T W Guentert; S Riegelman; L B Sheiner
Journal:  Br J Clin Pharmacol       Date:  1981-02       Impact factor: 4.335

4.  Divergence in pharmacokinetic parameters of quinidine obtained by specific and nonspecific assay methods.

Authors:  T W Guentert; R A Upton; N H Holford; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1979-06

Review 5.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

6.  Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state.

Authors:  J M St-Onge; G Sirois; M A Gagnon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983 Oct-Dec       Impact factor: 2.441

7.  Isolation, characterisation and synthesis of a new quinidine metabolite.

Authors:  T W Guentert; J J Daly; S Riegelman
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

Review 8.  Clinical pharmacokinetics of quinidine.

Authors:  H R Ochs; D J Greenblatt; E Woo
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

9.  Death and blindness due to overdose of quinine.

Authors:  E H Dyson; A T Proudfoot; L F Prescott; R Heyworth
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-06

10.  Gastrointestinal absorption of quinidine from some solutions and commercial tablets.

Authors:  T W Guentert; R A Upton; N H Holford; A Bostrom; S Riegelman
Journal:  J Pharmacokinet Biopharm       Date:  1980-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.